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1. Introduction
Cesarean section is among the most commonly performed surgeries in women and neuroaxial
anaesthesia is the technique of choice for this procedure. Although numerous side effects
related to obstetric anaesthesia had been described, [1, 2, 3, 4] subarachnoid anaesthesia has a
clear tendency to be used more often than epidural and combined spinal-epidural technique.
It is safe, easy to perform, effective, low failure rate, no systemic local anaesthetic toxicity,
inexpensive, prevents aspiration pneumonia, and has a high rate of maternal satisfaction. [5,
6, 7] Produces a deep anaesthesia, inhibits the stress response to surgery, blunts the autonomic
and somatic responses to pain, and facilitate breathing, coughing, sighing and early ambula‐
tion [8, 9] Finally, efferent sympathetic blockade results in increased blood flow to the blocked
area resulting in better wound healing. It also reduces the risk of deep vein thrombosis and
thromboembolism.
The main limitations of spinal anaesthesia are its short duration of action and do not provide
prolonged postoperative analgesia when it is performed only with local anaesthetics. Adding
adjuvants drugs to intrathecal local anaesthetics improves quality and duration of spinal
blockade, and prolongs postoperative analgesia. It is also possible to reduce dose of local
anaesthetics, as well as total amount of systemic postoperative analgesics. Several spinal
adjuvants have been used to improve spinal anaesthesia quality and to prolong postsurgical
analgesia. Intrathecal opioids are the most commonly utilized; fentanyl and sufentanil improve
neuroaxial anaesthesia, decrease trans operative pain and moderately prolong sensory block,
while morphine prolongs postoperative analgesia. Alpha2 adrenergic agonists clonidine and
dexmedetomidine shorten onset of action, and prolong duration of spinal anaesthesia.
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Ketamine, midazolam, neostigmine, magnesium sulphate and others spinal drugs are still
under investigation.
This chapter is an up to date of spinal additives currently used to enhance subarachnoid
anaesthesia for cesarean section and to produce subarachnoid postcesarean analgesia.
2. Spinal additives drugs for cesarean delivery
The use of subarachnoid additives in spinal anaesthesia for cesarean section has two main
objectives: to enhance spinal block and to produce effective and prolonged postoperative
analgesia. Reducing the dose of local anaesthetics used in spinal anaesthesia can decrease some
of the side effects such as maternal hypotension, high spinal block, and prolonged motor block.
By inducing better analgesia after cesarean section with intrathecal additives, the recently
given birth mother is better able to take care of her newborn, which immediately improves
mother-baby relationship, decreases prelacteal feeds (feeding any other substance before first
breastfeeding), which is closely related to urban residency, first-time motherhood, and
cesarean delivery. Prelacteal feed has been reported as high as 26.5%. It has several harmful
effects on the mother-newborn binomia. [10, 11] Immediate proper breast feeding even favor
neonatal analgesia for minimum invasive procedures like heel prick. [12]
Postoperative pain after cesarean section is common and more intense compared to postva‐
ginal delivery pain. [13] When this kind of pain is not prevented nor treated properly, it can
evolve to chronic pain which means a serious health problem. [14] Therefore, intrathecal
adjuvants play an important role not only in maternal analgesia, but in the future of the
newborn.
There are several adjuvant drugs used to enhance spinal anaesthesia; morphine is the most
frequently used and also many other opioid agonists such fentanyl, sufentanyl, hydromor‐
phone, diamorphine, and meperidine have been well studied and are part of our daily
armamentarium in this clinical scenario, as are some non-opioid drugs such clonidine. There
is a heterogeneous group including midazolam, neostigmine, magnesium, that needs more
research before they can be part of daily use as intrathecal adjuvants for C-section anaesthesia.
Table 1 summarizes the most commonly used spinal additives and some drugs under clinical
research in parturients undergoing cesarean delivery with spinal anaesthesia.
3. Spinal opioids
Opioids are the most commonly used analgesics to treat perioperative pain. Since the isolation
of morphine in 1804 by Friedrich Sertürner, a pharmacist´s apprentice in Germany, morphine
became widely used after 1815. Since then, a large number of opioids have been developed
modifying the 4, 5-epoxymorphinan ring structure. Opioids have a narrow therapeutic index
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with a large inter patient analgesic response variability; from poor analgesia to dangerous side
effects.
Morphine was the first spinal drug used to relieve pain, [15] Pert and Snyder [16] discovered
the opioid receptors in 1973, and three years after Yaskh and Rudy working at Yale published
their famous article entitled Analgesia mediated by a direct spinal action of narcotics, [17] which
encouraged animal and clinical research for the use of opioids and other neuroaxial additives.
Intrathecal opioids bind to opioid receptors localized in laminae I and II at the spinal dorsal
horn reducing nociceptive transmission. Opioids with high lipid solubility and low pKa results
in a extremely potent analgesic effect, rapid onset and short duration of action, conversely
opioids with diminished lipophilicity such is morphine, have a slow onset and prolonged
analgesia. Pharmacokinetically, subarachnoid injection of opioids follows a complex multi
compartmental model influenced by opioid properties and cerebro spinal fluid (CSF) dynam‐
ics. From the lumbar CSF they move inside the spinal cord binding dorsal horn opiate receptors
and also enter the bloodstream through the posterior radicular artery. Spinal opioids also
penetrate the dura mater into the epidural cavity and hence can reach the venous plexus of
Baston and reach the systemic circulation. They can also move in a cephalad-caudal direction
as a drug bulk flow. [18] This rostral migration is probably the most important factor to explain
the side effects of opioids, especially deleterious properties of morphine. There are other
possible sites where spinal opioids act to produce local anaesthetic effects blocking nerve
conduction, [19] or by reducing the release of GABA and glycine by a calcium independent
process from dorsal horn neurons. [20]
After local anaesthetics, opioids are the most commonly used drugs by this route providing
segmental analgesia. Clinicians have used them for more than 30 years in anaesthesia, for acute
pain, postoperative analgesia, and to treat cancer pain. [21, 22] Although spinal opioids are
used frequently, there are many unresolved disputes on the neurotoxicity of opioids injected
into the subarachnoid space. [23, 24, 25, 26]
In obstetrics patients, neuroaxial opioids use is a significant therapy for labour pain, in cesarean
section anaesthesia, and for postoperative pain. A very small dose of almost any opioid
delivered into the lumbar spinal space provides significant pain relief with virtually no risk to
mother or the fetus-neonate.
Morphine. It is the basic reference opioid to which all analgesics of its kind are compared. It is
a phenanthrene derivative, the prototypical agonist opiate at mu and kappa opioid receptors.
Has a benzene ring with a phenolic hydroxyl group at position 3 and an alcohol hydroxyl
group at position 6 and at the nitrogen atom. Its chemical formula is C17H19NO3. This opioid
can be administered by mouth, intravenously, intramuscular, subcutaneously, rectally,
intranasal, and through the neuraxial route. Has a significant amount first-pass liver metabo‐
lism and about 40 to 50% of the absorbed morphine reach the central nervous system. Most
morphine is eliminated by the kidneys. Its poor lipid solubility-a physical characteristic that
favors its behavior when injected into the intrathecal space-producing slow analgesic onset
with long duration and rostral migration that facilitates some of its side effects such as pruritus,
emesis, hypothermia, and respiratory depression. [27, 28]
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Although there are places where spinal opioids in obstetrics are not routinely used, [29] at
present time, neuraxial morphine is considered as the gold standard to treat pain after C-
section and has become a conventional practice in many countries. It is mentioned in textbooks
on obstetric and neuroaxial anesthesia [30, 31, 32] as a conventional method. Most authors
have reported that 100 to 200 µg of spinal morphine plus regular or low doses of a PPX local
anaesthetic or lidocaine are enough to provide an excellent block, high quality postcesarean
analgesia, decreased needs of rescue postoperative analgesics, with few side effects. [33-37]
Weigl and coworkers [38] compared intrathecal morphine 100 µg versus spinal fentanyl 25 µg
added to 0.5% hyperbaric bupivacaine 7.5 to 15 mg in 60 parturients. Intrathecal morphine
drastically prolonged the time for first rescue analgesic, and also reduce postoperative
meperidine [47 mg versus 130 mg) when compared to fentanyl. Itch was more often observed
in patients treated whit morphine. There was no significant difference in the incidence of
postoperative nausea and vomiting between both groups. There were few patients in the
morphine group who required additional intravenous opioids during surgery. Bejar et al from
Argentina [39] demonstrated that intrathecal morphine 100 µg were better than systemic
morphine, although the former had more incidence of itching. In a Brazilian study [40] the
authors found that 50 µg of intrathecal morphine produced equal analgesia after cesarean
section as 100 µg, but with less incidence of pruritus. Cortes-Blanco et al from México [36],
compared morphine 100 µg versus 200 µg added to intrathecal ropivacaine 15 mg in 80 women
undergoing cesarean delivery. The analgesic effect lasted 24 to 30 hours, with a low need of
postoperative rescue analgesic; ketorolac was used in equal dose in both groups (p>0.05].
However side effects were more frequent in those women receiving morphine 200 µg: pruritus
30% versus 55%, nausea 10% versus 30%, and vomiting 5% versus 12.5%. The authors
recommended 100 µg as the ideal dose in Mexican parturients undergoing C-section.
Morphine can be coadministered with sufentanil. Draisci et al [41] compared spinal adminis‐
tration of morphine 150 µg plus sufentanil 5 µg versus spinal sufentanil 5 µg plus a single
subcutaneous morphine 10 mg in 64 pregnant women undergoing elective cesarean under
spinal anaesthesia with hyperbaric bupivacaine 10 mg. Both groups received 1 g acetamino‐
phen every 6 hours and intravenous tramadol was used if VAS was superior to 4. Coadmi‐
nistration of two opioids resulted in prolonged analgesia, less need of tramadol, and less
incidence of nausea and no difference in pruritus incidence. Using a combination of spinal
morphine 100 µg plus sufentanil 2.5 µg, Bouvet et al [42] determined that the ED50 and ED95
of intrathecal levobupivacaine is 12.9 mg. For less levobupivacaine dose, the authors recom‐
mended to use spinal-epidural combined technique for C-section anaesthesia.
Notwithstanding the multiple investigations to determine the ideal dose, a recent study
questioned the best dose of intrathecal morphine for postcesarean analgesia. Wong and
coworkers [43] compared the most used doses; 100 versus 200 µg and concluded that the higher
dose produce better analgesia but with more nausea, so morphine dosing has to be based on
patient preference for analgesia versus emesis.
Recently, in order to avoid spinal morphine side effects, some authors compared ultrasound
guided tranversus abdominis plane block versus intrathecal morphine; although ultrasound-
guided transversus abdominis plane block is an effective method to supply pain relief after
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cesarean delivery, 100 µg and 200 µg subarachnoid morphine provided superior analgesia,
but emesis and itching were more frequent. This block could be a reasonable alternative when
morphine cannot be used. [44, 45]
Hydromorphone. Also known as dihydromorphinone, is a semi-synthetic opioid widely used
to treat pain. It is 5 to 11.1 times more potent than morphine, highly soluble in water, with
intermediate lipid solubility. The chemical name is 4, 5α-epoxy-3-hydroxy-17-methylmor‐
phinan-6-one hydrochloride, with a molecular formula C17H19NO3 and molecular weight
285.33766. Has a similar pharmacokinetics and duration of action than morphine, is extensively
metabolized by the liver to hydromorphone-3-glucoronide with no analgesic effects, 62% of
the oral dose is eliminated by this gland on the first pass. Hydromorphone cross the blood
brain barrier and reach concentrations in the CNS faster than morphine. Is better tolerated in
patients with kidney failure due to a lack of an active metabolite, but its half life can increase
to as much as 40 hours. [28, 46]
In a retrospective research, Rauch [47] found that 100 µg of spinal hydromorphone produced
a comparable onset of pain relief to 25 µg of subarachnoid fentanyl, with a prolonged analgesia
(p<.001] and proposed this opioid as a substitute of intrathecal morphine. Beatty et al [48]
compared intrathecal hydromorphone 40 µg versus intrathecal morphine 100 µg in 114
parturients undergoing cesarean section. They found no statistical differences regarding
opioid related side effects, rescue analgesics needs or postoperative pain intensity during the
first 24 hours. In non obstetric patients [49] nausea is related significantly in a dose-dependent
manner. In patients with known allergy to intrathecal morphine, hydromorphone can be used
spinally with better analgesic results. [50]
Diamorphine. Also known as heroin, is an pure agonist opioid analgesic 1.5 to 2 times more
potent than morphine. In 1874 Charles Write boiled morphine and created heroin. Its chemical
name is 4, 5-Epoxy-17-methylmorphinan-3, 6-diyldiacetate hydrochloride monohydrate or
[5α, 6α)-7, 8-Didehydro-4, 5-epoxy-17-methylmorphinan-3, 6-diol diacetate (ester), with a
molecular formula C21H23NO5. After oral ingest, diamorphine undergoes extensive liver first
pass metabolism via deacetylation, transforming into a 6-monoacetylmorphine and morphine.
Injected diamorphine, promptly cross the blood-brain barrier and is transformed into mor‐
phine by deacetylation, acting over the µ opioid receptors. This opioid can be given by the
same routes as morphine in approximately half dose. Its high liposolubility [200 times more
liposoluble than morphine) is against rostral migration, consequently reduces the possibility
of side effects due to its action on the CNS, especially late respiratory depression. Diamorphine
is associated with more euphoria than morphine. [51, 52] This opioid is used for the treatment
of pain; severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain,
including end-stage cancer and other painful terminal illnesses. Although diamorphine is used
for the cure of pain, it is also used illegally by addicts. [51]
Diamorphine had been used neuroaxialy for intraoperative and postcesarean analgesia.
Epidural 5 mg produces similar analgesia to 250 µg injected into the subarachnoid space, but
with less emesis. [52] Equal doses of diamorphine and intrathecal morphine produce similar
postcesarean analgesia but the former has lower frequency and intensity of emesis and
pruritus, which is attributed to its greater lipophilicity. [53] Most studies have compared
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intrathecal doses from 125 up to 375 µg, with similar analgesic results, but a wide outcome
regarding incidence of pruritus, nausea and vomit. [54] In a double blind randomized
controlled investigation Wrench and coworkers [55] compared spinal diamorphine 0, 100, 200,
and 300 µg added to spinal block and systemic diclofenac-paracetamol plus subcutaneous
diamorphine for breakthrough pain. They found that 300 µg resulted in better analgesia, but
a dose related increase in the incidence of pruritus. In this study, nausea and vomit did not
have a dose dependent effect. Spinal diamorphine 300 µg was comparable to intrathecal
fentanyl 20 µg regarding needs of intraoperative analgesics supplementation, but the former
opioid produced longer postoperative analgesia. [56] Diamorphine 250 µg combined with
fentanyl 15 µg as additive to spinal bupivacaine were not superior to diamorphine alone. [57]
Sarvan et al [58] found in 200 cesarean done under spinal anaesthesia with 12.5 mg hyperbaric
bupivacaine that the ED [95] of 400 µg subarachnoid diamorphine is needed to prevent
intraoperative analgesic supplementation. This high dose increased time for first request
postoperative analgesic, but also augmented the incidence of nausea, vomiting and pruritus.
The addition of intrathecal diamorphine does not appear to influence block height. [60]
Fentanyl. Is the oldest synthetic piperidine opioid agonist, 100 to 80 times more potent than
morphine, chemically identified as N-[1-phenethyl-4-piperidyl) propionanilide citrate [1:1]
with a molecular weight of 528.60. The empirical formula is C22H28N2O • C6H8O7. The phar‐
macokinetics of fentanyl can be described as a three-compartment model, with a distribution
time of 1.7 minutes, redistribution of 13 minutes and a terminal elimination half-life of 219
minutes. The volume of distribution for fentanyl is 4 L/kg. It is primarily transformed in the
liver, demonstrates a high first pass clearance and releases approximately 75% of an intrave‐
nous dose in urine, mostly as metabolites with less than 10% representing the unchanged drug.
It has a rapid onset of action when the drug is given intravenously or intrathecally. Fentanyl
has less emetic activity than either morphine or petidine. [27, 28, 30, 32]
After intrathecal morphine, fentanyl is probably the most widely used opioid in patients
undergoing cesarean section; improves quality of spinal anaesthesia, reduces dose of local
anaesthetics, but has little impact on prolonging postoperative analgesia. [60, 61, 62] Most used
doses of intrathecal fentanyl range from 15 to 25 µg, although this opioid had been investigated
in a wide range as of 2.5 up to 50 µg for cesarean delivery. It can be safely mixed with lidocaine,
bupivacaine, levobupivacaine, ropivacaine, or mepivacaine. [63, 64, 65, 66] The first study
using intrathecal fentanyl was done by Hunt at [67] from Brigham and Women´s Hospital in
Boston USA; they evaluated 0, 2.5, 5, 6.25, 12.5, 25, 37.5 and 50 µg of fentanyl added to spinal
hyperbaric bupivacaine 0.75% in 56 parturients undergoing cesarean delivery. Sixty seven
percent of patients in the control group needed supplemental intraoperative opioids. None of
the parturients who received more than 6.5 µg fentanyl required transoperative opioids. Time
for first analgesic request was 33.7±30.8 min (mean±SD) in the control group and increased to
130±30 min (p<0.05] in those women treated with 6.25 µg fentanyl. Duration of effective
analgesia was significantly longer in this group 192±74.9 min versus 71.8±43.2 min (p<0.05].
Bigger doses had no effect on effective analgesia. Itching was increased with 25 and 50 µg.
There were no side effects in the neonates. They concluded that the optimal dose of spinal
fentanyl is 6.5 µg. Most authors reported that higher doses from 12.5 to 25 µg [68, 69] are safe
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and enhance spinal blockade, trans cesarean analgesia and immediate postsurgical analgesia,
without increasing side effects.
The optimal dose of 12 mg 0.5% hyperbaric bupivacaine for C-section was reduced to 8 mg
adding 10 µg of spinal fentanyl. [71] The addition of fentanyl 20 µg to 10 mg hyperbaric
bupivacaine 0.5% did not alter significantly spirometric parameters in 40 parturients after
cesarean delivery compared with bupivacaine alone. [72]
In summary, the addition of intrathecal fentanyl to local anaesthetics used in cesarean section
reduces the need for intraoperative analgesics, improves postoperative analgesia for a brief
period of time of 2-4 hours, has no effect on the subsequent analgesic doses. The aforemen‐
tioned doses are very safe for the mother and newborn, and its side effects are minimal.
Sufentanil citrate. Synthesized in mid-1970s, was introduced into clinical practice 10 years later.
Sufentanil is a potent pure agonist opioid, 6-10 times more potent than fentanyl, chemically
designated as N-{4-(Methoxymethyl)-1-[2-[2-thienyl)ethyl]-4-piperidinyl}-N-phenylpropana‐
mide, with a molecular weight of 578.68. The molecular formula is C22H30N2O2S. [73, 74]
This opioid is a fundamental part of daily anaesthesia armamentarium. As spinal additive for
cesarean section, sufentanil had been used in doses ranging from 1.5 to 20 µg. The initial clinical
research by Courtney et al [75] compared 0, 10, 15 and 20 µg as spinal adjuvant to 0.75%
hyperbaric bupivacaine 10.5 mg in 37 women undergoing elective cesarean delivery. Analgesia
was prolonged significantly in all patients treated with sufentanil, but pruritus incidence was
notably increased. Apgar score and Early Neonatal Neurobehavioral Scale were within normal
limits. The most recommended dosages range from 2.5 to 5 µg improving spinal anaesthesia
and postoperative analgesia, with mild side effects. [28, 76, 77, 78, 79] Braga and coworkers [78]
compared sufentanil 0, 2.5, 5 and 7.5 µg added to spinal hyperbaric bupivacaine 12.5 mg. Onset
block was significantly shorter in women treated with the opioid and postoperative analgesia
was longer in patients receiving 5 and 7.5 µg sufentanil. Those women who received higher
doses had more incidences of sedation and pruritus. A prospective, randomized, double-blind,
controlled trial [79] found that smaller doses also produced excellent operative analgesia and
prolonged postcesarean analgesia; the authors compared 0, 1.5, 2.5 and 5 µg sufentanil added
to hyperbaric bupivacaine 0.5% 12.5 mg in 100 pregnant women undergoing elective C-section.
Women treated with the opioid had no operative pain, postoperative analgesia was prolonged
and rescue analgesic was similar in those women treated with sufentanil. Itch was more
frequent in the 2.5 and 5 µg sufentanil groups than in placebo or 1.5 µg sufentanil. There were
no differences in the newborn evaluation. Bang et al [80] compared a placebo group versus 2.5
versus 5 µg sufentanil added to spinal hyperbaric bupivacaine and reported no significant
differences among the 3 groups regarding the maximum sensory levels and motor block.
Patients receiving 5 µg sufentanil had slower recovery of the sensory block. Intrathecal
sufentanil enhanced intraoperative analgesia, muscle relaxation and duration of effective
analgesia in a dose related response. Occurrence of hypotension, sedation, and itching were
also opiate dose related. The addition of 2.5 µg sufentanil to 0.5% levobupivacaine produced
faster onset time for sensory and motor block than levobupivacaine alone. It also prolonged
postoperative analgesia and reduced analgesic needs. These results were similar to the
addition of intrathecal 10 µg fentanyl. [81] Sufentanil 5 µg added to spinal local anaesthetics
Spinal Additives in Subarachnoid Anaesthesia for Cesarean Section
http://dx.doi.org/10.5772/58851
73
produce similar results as spinal morphine 200 µg regarding anaesthesia quality, operative
analgesia, incidence of maternal emesis as well as newborn safety, but morphine postoperative
analgesia was longer 19.5± 4.7 hours versus 6.3±5.2 hours p< 0.05]. [28, 82]
Adding 5 µg sufentanil to ropivacaine appears to be optimal, as it increases the efficacy of
spinal analgesia without increasing the incidence of side effects, and ropivacaine dose can be
reduced up to 28% of ED50 for C-section. [83, 84, 85] Mixing 5 or 10 µg sufentanil with 75 mg
lidocaine 5% in parturients undergoing cesarean delivery prolonged spinal anaesthesia
compared to placebo, but also produced mild to moderate respiratory depression, which was
more important with 10 µg 46.7% (p<0.001]. [86]
Several authors had compared fentanyl versus equianalgesic doses of intrathecal sufentanil
administered concurrently with hyperbaric bupivacaine 0.5% for cesarean delivery; both
opioids abolished intraoperative opioid requirements, and discreetly prolonged postcesarean
analgesia although sufentanil produced more prolonged analgesia without significative side
effects on the parturient and neonate. [87, 88, 89]. Bremerich et al [90] reported that the
association of sufentanil-levobupivacaine was better than fentanyl added to intrathecal
bupivacaine o levobupivacaine. A study from Brasil [91] showed that intrathecal sufentanil
2.5 µg combined with morphine 80 µg during anaesthesia with hyperbaric bupivacaine
decreased significantly the immediate incidence of postcesarean shivering from 62.5% to 32.5%
(p<0.007].
Meperidine (Pethidine).Meperidine is a synthetic opioid agent, and is the only opioid that has
significant local anaesthetic activity in the dose range normally used for analgesia. Was
synthesized in 1939 as an anticholinergic agent, but was soon discovered to have analgesic
properties. It belongs to the phenylpiperidine family; it is ethyl 1-methyl-4-phenylisonipeco‐
tate hydrochloride, readily soluble in water. Molecular formula is C15H21NO2, and has a
molecular weight 247.33274. Meperidine is quickly hydrolyzed in the liver to petidinic acid,
and is also demethylated to norpetidine, a neurotoxic metabolite. Meperidine metabolites are
further conjugated with glucoronic acid and excreted into the urine. [28, 30, 92, 93].
There are reports using intratecal meperidine mixed with local anaesthetics in several clinical
settings; in obstetric patients, meperidine has been used as spinal adjuvant, as a single agent
for epidural or subarachnoid for labor pain, and also for anaesthesia-analgesia in cesarean
delivery. As spinal sole drug for cesarean section, meperidine had been uses with good results.
[94, 95, 96]. Cheun and Kim [96] studied 182 parturients undergoing cesarean delivery; they
used meperidine 50 mg combined with 10% dextrose 0.5 mL injected in the lumbar spinal space
achieving sensory and motor blockade in all patients, prolonged analgesia [453±158.1 min) and
motor recovery [75.9±17.2 min). Side effects were minimum and included nausea, hypotension
and pruritus. Eighteen patients had mild pain at the end of surgery. There were no side effects
on the newborns.
Yu and coworkers [97] compared meperidine 10 mg plus intrathecal 0.5% hyperbaric bupiva‐
caine 10 mg versus hyperbaric bupivacaine alone. They found prolonged postcesarean
analgesia (mean 234 min, 95% confidence interval 200-269 min) versus control group (mean
125 min, 95% confidence interval 111-138 min; p<0.001]. Woman receiving meperidine had
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more incidence of intraoperative emesis [11 versus 3; p=0.02]. Reducing meperidine dose to
7.5 mg also produces similar results, enhancing local anaesthetics spinal block and prolonging
postcesarean analgesia. [98, 99] Meperidine is a good substitute in patients with allergy to local
anaesthetics. [100, 101]
Nalbuphine. Is a synthetic agonist-antagonist opioid belonging to the phenanthrene group.
Chemically is 17-(cyclobutylmethy1]-4, 5a-epoxymorphinan-36a, 14-triol hydrochloride,
molecular weight 393.91, soluble in water [35.5 mg/mL at 25oC) and ethanol [0.8%), Pka 8.71
and 9.96. The molecular formula is C21H27NO4 HCl. It is structurally related to naloxone, an
antagonist of the opiate receptors, and to oxymorphone, an analgesic agonist of the opiate
receptors. It has an elimination half-life (t1/20] of about 5 hours in normal people. Because
nalbuphine is mainly eliminated from the body by biotransformation, nalbuphine undergoes
an extensive first-pass metabolism. [102, 103]
Rawal and coworkers studied several spinal opioids in sheep, including nalbuphine; [104]
although spinal nalbuphine was not the less neurotoxic, the authors found that this opioid was
associated with relative minor behavioral and EEG changes, sedation, spinal cord mild
inflammatory and neuronal changes. Following intrathecal nalbuphine, the above-mentioned
changes were similar to those seen in control animals. One animal developed motor impair‐
ment during 60 minutes. The analgesic effect of spinal nalbuphine can be reverted by naloxone.
[105] To date, no clinical reports of this opioid have mentioned secondary neurological
damage, although this observation has not enough clinical evidence. There is little clinical
research with this opioid injected intrathecally. Nalbuphine been used as additive for spinal
anaesthesia in several clinical settings in doses from 200 to 1600 µg. [106, 107, 108]
The first study with intrathecal nalbuphine in obstetric patients was conducted by Culebras
et al; [109] in a double blind study they injected nalbuphine 200, 800, 1600 µg mixed with
hyperbaric 0.5% bupivacaine versus morphine 200 µg with bupivacaine in 90 parturients
undergoing cesarean delivery. Only women receiving morphine and nalbuphine 200 µg
reported transoperative pain. In the nalbuphine groups, postoperative analgesia lasted longest
with the 0.8 mg dose, but postoperative analgesia was significantly prolonged in the morphine
group (p<0.0001]. Itching incidence was superior with spinal morphine as well as postcesarean
nausea and vomiting. There was no maternal or newborn respiratory depression. Culebra´s
article was accompanied by an editorial written by Yaksh; [110] most of his commentaries were
regarding the lack of solid evidence about the neurotoxicity of nalbuphine and emphasized
that benefits does not outweigh the risks to use this the opioid by the spinal route.
Yoon et al [111] found that an intrathecal mixture of nalbuphine 1000 µg, morphine 100 µg
and hyperbaric 0.5% bupivacaine 10 mg for cesarean delivery strengthen intraoperative
analgesia compared with morphine alone, but this combination reduce postcesarean duration
of complete analgesia and had no effect on the incidence of itch. In a recent randomized, double
blind article using intrathecal nalbuphine for postcaesarean analgesia there were no differen‐
ces between nalbuphine 800 µg versus 25 µg fentanyl associated with hyperbaric 0.5%
bupivacaine 10 mg; both opioids produce transoperative analgesia and early postoperative
analgesia. [112]
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4. Spinal opioids side effects
As described in the preceding paragraphs, intrathecal opioids as adjuncts to local anaesthetics
are very safe in spinal anaesthesia for cesarean section, although may have sporadic potentially
life-threatening events. There is variety of side effects which are worth to be discussed briefly.
These side effects are due to different factors such as pharmacological and pharmacodynamic
characteristics of each opioid, the injected dose, and type of patient. Opioids with high
liposolubility have less risk of rostral migration and lower incidence of CNS side effects. Larger
doses will have higher incidence and severity of CNS deleterious effects.
Respiratory depression is a deleterious side effect which may have serious consequences like
respiratory arrest and even death. Fortunately, it is a very rare event. This complication can
occurs as quickly as 15 to 20 minutes after injection of lipophilic opioids, but with water soluble
opioids the event is late. [113, 114, 115] Morphine intrathecal doses higher than 300 µg are
associated with more episodes of respiratory depression. [116] It is mandatory to closely
monitor all patients receiving neuroaxial opioids. Besides clinical surveillance, pulse oximetry
monitors are used by most clinicians, although the use of transcutaneous carbon dioxide
monitor has been recommended recently. [117] It is prudent to give prophylactic nasal oxygen.
When respiratory depression is detected, it should be managed with intravenous naloxone.
Also intravenous nalbuphine has been used with excellent results. On rare occasions it is
necessary to use ventilatory support with endotracheal intubation.
Emesis and pruritus are the most frequent side effects. Nausea and vomiting are similar,
but  pruritus  increased  in  direct  proportion  to  the  dose  of  intrathecal  morphine  (linear
regression, p=0.0001]. Although emesis due to spinal morphine do not interfere with early
feeding after surgical delivery, [118] it is an unpleasant nuisance that can be prevented by
various drugs administered immediately after the umbilical  cord is  ligated;  ondansetron
4-8 mg, ganisetron 3 mg, tropisetron 5,  droperidol 1.25 mg, dexamethasone 4-8 mg and
diphenydramine 30 mg. [119, 120] Metoclopramide 10 mg does not appear to be effective
for emesis prophylaxis in this patient population. Serotonin [5-HT3] receptors antagonists
had poor effect preventing itching, while the prophylactic or therapeutic administration of
droperidol 1.25. mg, nalbuphine 5-10 mg, pèntazocine 15 mg, butorphanol 1 mg followed
by intravenous infusion of 0.2 mg/h. [121, 122, 123]
Severe postoperative hypothermia has been described in a variety of surgical procedures,
including cesarean section done under epidural or spinal therapeutic doses of morphine. The
mechanism is not well known but it is said that could be mediated by morphine cephalad
spinal spread reaching opioid receptors and altering the temperature set point in the hypo‐
thalamus. It can be treated effectively with naloxone or lorazepam. [124-129]
5. Non opioids spinal additives
As we reviewed, spinal opioids side effect profiles may have some limitation to be used as
adjuvants in cesarean delivery; pruritus, nausea, vomiting, and urinary retention are non fatal
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deleterious side effects but bother most patients. Late respiratory arrest and hypothermia after
usual opioid doses has been seldom reported in the literature. There are several non-opioide
adjuvants that have been studied for the purpose to enhance spinal anaesthesia and to prolong
and augment postcesarean analgesia [130], being alpha2 agonists the most promising agents.
[131, 132] Spinal adjuvants like magnesium, ketamine, neostigmine are mostly used for clinical
research, and nowadays is no prudent to recommend these drugs as a routine practice.
Clonidine. Eisenach et al demonstrated that epidural/spinal clonidine did not affect sheep fetus,
but fetal bradycardia may limit the efficacy of spinal clonidine if used more than 10 µg/kg in
obstetrics. [133, 134] Many clinical studies have been done using neuroaxial clonidine mixed
with local anaesthetics and/or opioids, and as solo drug in obstetrics patients. Low doses of
spinal clonidine in subarachnoid anaesthesia for cesarean delivery are reported to enhance the
anaesthetic block, to reduce dose of local anaesthetics, and to extend postoperative analgesia.
There are studies mixing clonidine with intrathecal opioids, as there is a synergic effect.
In  a  double  blind  study Filos  et  al  [135]  carried  out  their  investigation  to  evaluate  the
analgesic effect of sole clonidine in women undergoing elective cesarean delivery, 150 µg
were injected 45 minutes after general anaesthesia and compared to intrathecal saline as
control group. Pain intensity was lower in clonidine treated parturients 20 to 120 minutes
after spinal injection (p<0.05],  request for first analgesic was also longer in the clonidine
group 414±128 minutes versus 181±169 minutes (p<0.01]. Clonidine side effects were severe;
hypotension with a maximal reduction of  systolic  [15±9%),  diastolic  [22±12%) and mean
arterial  pressure  [18±12%).  Sedation  was  significantly  more  intense  compared  to  saline
(p<0.05]; also dried mouth was more commonly (p<0.01]. Although these data suggest that
150 µg subarachnoid clonidine is effective to treat acute pain after cesarean section, it has
side effects such as hypotension, sedation, and dryness of mouth. Two years later, the same
authors [136] performed a different study comparing 150, 350 and 450 µg of spinal clonidine
to  evaluate  the  dose-response  hemodynamic  and  analgesic  responses  in  the  immediate
postoperative period of cesarean section under general anaesthesia. They found less pain
in all groups in a dose dependent mode: request for first analgesic 402±75 min, 570±76 min,
and 864±80 minutes respectively (p<0.01-0.001]. Clonidine reduced mean arterial pressure
compared  with  baseline  only  in  those  patients  treated  with  150  µg  [21±13%,  p<0.05].
Sedation  was  evident  in  all  groups.  Respiratory  rate  and  motor  activity  of  the  lower
extremities were unaffected in all three groups. The hemodynamic stability after 300 and
450 µg suggested a pressor consequence at peripheral sites. This investigation demonstrat‐
ed a dose related analgesia after spinal clonidine at doses as great as 450 µg. Studies with
lower  doses  of  clonidine  has  shown satisfactory results.  Peach et  al  [137]  in  a  random‐
ized,  double  blind  trial  compared  intrathecal  clonidine  mixed  with  fentanyl  15  µg  and
morphine µg versus clonidine plus morphine in 240 women undergoing cesarean deliv‐
ery with hyperbaric  0.5% bupivacaine.  Using a  dose finding analysis  the authors  found
similar comparable postoperative efficacy and side effects for groups receiving morphine
100 µg with clonidine 60,  90,  or  150 µg and concluded that  a multimodal approach for
postcesarean analgesia, using subarachnoid bupivacaine, fentanyl,  morphine 100 µg, and
clonidine 60 µg, improves pain relief compared with morphine 100 µg or clonidine 150 µg
alone, but increases intraoperative sedation and may increase perioperative vomiting. Other
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investigators have found that clonidine 75 µg is a safe dose; prolong the anesthetic block
and enhance postoperative analgesia, with minimal side effects and no harm to the newborn
[132, 138, 139] Van Tuijl et al [140] compared 15 µg, 30 µg and 60 µg of clonidine added
to hyperbaric bupivacaine 0.5%; the authors found a dose dependent variability of analgesia
duration and sedation. Duration of analgesia was significantly higher in those patients who
received  clonidine  60  µg  as  compared  to  the  other  two  groups  [598.7±140.47  versus
436.65±149.84 and 387.1±97.05 min respectively). Sedation was also more in the highest dose.
In this study the authors recommended 15 µg and 30 µg doses due to good postopera‐
tive analgesia and less sedation.
It has been mentioned that mixture of hyperbaric local anaesthetics with clonidine should
not be done in one syringe before injection into the subarachnoid space, but to inject each
drug in separate syringes in order to avoid syringe interactions, in particular changes in
the  density  of  local  anaesthetics.  Sachan  et  al  [141]  studied  the  differences  between
hyperbaric bupivacaine mixed with clonidine in the same syringe just prior to subarach‐
noid  injection  versus  separate  administration  in  60  parturient  undergoing  cesarean
deliveries. Those women who received clonidine 75 µg plus hyperbaric bupivacaine 0.5%
10 mg contained in one syringe had shorter analgesia time [337±18.22 min) versus those
patients receiving same drugs but applied in separated syringes [474.33±20.79 min), p=0.000.
Moreover, time to reach highest sensory level and complete motor block was significant‐
ly less, without any major haemodynamic instability in those women injected in a sequen‐
tially manner. As a single drug, subarachnoid clonidine is not recommended for anaesthesia
neither for postcaesarean analgesia.
Should we administer intrathecal clonidine in obstetric patients? Under the results of clinical
investigations done by many authors in different countries, intrathecal clonidine is a safe
drug in obstetric patients when recommended doses are observed, but more clinical studies
are needed to adequately respond to this  question.  [131]  Moreover,  we have to keep in
mind that the FDA maintains its recommendation not to use epidural clonidine in obstetrics.
This organization does not mention the use of intrathecal clonidine in this clinical scenar‐
io.  For  more  information  about  intrathecal  clonidine  please  read  the  chapter  entitled
Intrathecal clonidine as spinal anaesthesia adjuvant. Is there a magical dose? included in this book.
Midazolam. A water soluble imidazobenzodiazepine, highly liposoluble in vivo, with a rapid
onset of action and high metabolic clearance. Chemically is 8-chloro-6-[2-fluorophenyl)-1-
methyl-4H-imidazo [1, 5-a] [1, 4] benzodiazepine hydrochloride, and the molecular formula
C18H13ClFN3•HCl, with a molecular weight of 362.25. [142] For an extended information on
midazolam, we refer you to the chapter included in this book entitled Midazolam in spinal
anaesthesia: intrathecal or intravenous? written by Beyazit Zencirci.
A preservative free midazolam administered by continuous intrathecal infusion to sheep and
pigs in doses from 5 to 15 mg/day during 43 days demonstrated that behavior, neurological
function, and vital signs were normal. There were no data of neurological damage, except mild
inflammation surrounding the catheter tract that was also observed in animals treated with
placebo. [143] There are few articles using intrathecal midazolam for cesarean section. In a
prospective, randomized, double-blind, placebo controlled study [144] the authors compared
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1 and 2 mg of midazolam added to subarachnoid bupivacaine 10 mg versus plain bupivacaine.
Request for first analgesic was 4.3±0.7 versus 6.1±1.0 versus 3.8±0.5 hours, respectively.
Supplemental diclofenac were significantly less in those women treated with midazolam 2 mg
[93±29 mg) compared with midazolam 1 mg [148±16 mg) and plain bupivacaine [145±12 mg).
Time to block regression was longer in plain bupivacaine group B [182±30 minutes) compared
with midazolam 1 mg [152±32 minutes) and midazolam 2 mg group B [126±20 minutes) (both
p<.001]. Interesting, patient who did not receive intrathecal midazolam had higher incidence
of nausea and vomiting. Arterial pressure, heart rate, oxygen saturation, sedation score, and
time to first void were comparable between groups. Karbasfrushan et al [145]. compared
intrathecal midazolam 2 mg added to bupivacaine 10 mg versus plain bupivacaine in women
undergoing elective cesarean. Patients treated with midazolam had significant pain relieve at
15 and 120 min after surgery, but there were no significant differences between the groups
regarding the intensity of pain 5, 30, 60 and 240 min after the surgery. Request for first analgesic
was 178.06±77.33 versus 142.18±55.19 min. Duration of analgesia and regression for sensory
analgesia was similar in both groups, but nausea and vomiting were higher in the midazolam
group. Salimi et al [147] use a combination of 2 mg midazolam plus 5 µg sufentanyl intrathe‐
cally versus sufentanyl alone for labour pain in 80 parturients. Analgesia was enhanced and
prolonged significantly [185±15.2 min versus 92±12.7 min p=0.001]. No significant side effects
were observed in both groups.
Magnesium sulfate. Is a chemical compound containing magnesium, sulfur and oxygen.
Magnesium sulphate is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA)
receptor, therefore can interfere nociceptive modulation. There is controversy about the
neurotoxicity of magnesium sulfate injected into the neuraxis. [148, 149] In a contemporary
study conducted in Sprague-Dawley rats, Ozdogan and coworkers [149] were able to demon‐
strate on electron microscopic examinations, that single or repeated spinal injection of
magnesium sulphate 0.15% produced significant neurodegeneration. Nonetheless, there are
clinical studies that support the use of this ion via neuraxial-epidural or subarachnoid-in
diverse clinical scenarios, [150, 151, 152] including in the obstetric field, showing to prolong
analgesia without important side effects in healthy and pathologic parturients.
It  has  been used through epidural  [153,  154]  and spinal  via  for  cesarean delivery,  with
highly variable results. Ghrab et al [155] studied 105 women undergoing cesarean section
with  spinal  anaesthesia.  They  found  that  adding  magnesium  sulphate  100  mg  to  mor‐
phine  100  µg  improved  the  quality  and  duration  of  postcesarean  analgesia  without
augmenting the incidence of harmful side effects. Jabalameli and Pakzadmoghadam [156]
compared 0, 50, 75 and 100 mg magnesium sulphate added to spinal bupivacaine in 132
parturients  undergoing cesarean delivery.  Magnesium produced a  delay in  the onset  of
sensory and motor blockade. Duration of sensory and motor blockade were longer in those
women treated with 75 a 100 mg doses. Patients who did not receive magnesium had a
shorter recovery time and needed more postoperative analgesic (p<0.001]. In patients with
mild preeclampsia [157]  adding magnesium sulphate 50 mg to 0.5% hyperbaric  bupiva‐
caine and fentanyl 25 µg induced a slower onset of motor and sensory block, prolonged
duration of spinal anaesthesia and motor block and reduced needs of diclofenac during 24
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hours. No harmful side effects were noticed. As Faiz et al mentioned, spinal magnesium
improved perioperative shivering in women undergoing elective caesarean delivery. [158]
In a prospective, randomized, double blind study in 90 women undergoing cesarean section,
Unlugenc et al [159] were unable to probe that 50 mg magnesium sulphate have any benefit
over  spinal  anaesthesia  with  bupivacaine  0.5%.  Adding  this  adjuvant  to  10  mg  spinal
bupivacaine  did  not  shorten  onset  time  of  sensory  and  motor  blockade  or  prolonged
duration of subarachnoid anaesthesia as compared to spinal fentanyl.
6. Conclusions
Across the world, subarachnoid anaesthesia is the most used anaesthetic procedure for
Cesarean delivery. Compared to general and epidural anaesthesia, its main disadvantage is a
short duration action and most important, the lack of prolonged postoperative analgesia. These
two negative factors had been overcome with the addition of drugs that act enhancing quality
and durability, while they managed to decrease the dose of local anaesthetic and prolong
postoperative analgesia. Provision of postcesarean delivery analgesia is of great consequence
since it accelerate early ambulation, decreases maternal morbidity, improves parturient
outcome, decrease cost, and most important augment the quality of the mother-infant
relationship from the moment of birth.
When planning spinal anaesthesia for cesarean section there are different local anaesthet‐
ics  and  various  adjuvants  that  enhance  the  technique  and  favor  better  outcome of  our
patients. It is vital that the choice of adjuvants drugs be rationally and according to each
clinical  condition and local  availability of these drugs.  Although there is  no gold stand‐
ard  for  a  perfect  spinal  anaesthesia  and  postcesarean  analgesia,  in  this  millennium  is
mandatory to provide the best available care. As reviewed, there is a large list of options
and the choice  is  mostly  determined by drug safety  and accessibility,  the  experience of
anaesthesiologists, and monetary factors.
When adjuvants are selected for neuroaxial anaesthesia, it is mandatory to use drugs that are
not neurotoxic and are free of preservatives.
Spinal Adjuvants Dose range in µg Effects Side effects
Morphine
50-400
Reduce DE50 and DE95 of
spinal LA
PONV dose related
Pruritus moderate to severe
Prolonged POA Urinary retention
Recommended
dose 100 Reduce analgesics
Respiratory depression (rare)
Hypothermia (very rare)
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Spinal Adjuvants Dose range in µg Effects Side effects
Hydromorphone
40-100
Prolonged POA PONV similar no morphine





PONV similar no morphine
Enhance POA
Recommended
dose 300 Reduce POP analgesics doses








Reduce spinal LA dose
Less itchichin tha morphine
Reduce intraoperative
analgesics
Enhance POA for 2-4 hours
Sufentanyl
1.5 - 20 Rapid onset
Dose relates itchnig
Enhace spinal blockade
Reduce spinal LA doses Posoperative sedation
Improve trans cesarean
analgesia
PONV higher than fentanyl
Recommended
dose 5 Short prolongation of POA
Reduce PO analgesic needs
Meperidine 7000 to 10, 000 Rapid onset High incidence of transurgical
vomitigD Improve spinal anaesthesia
Recommended
dose, 500 Prolongs POA PONV are high
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PONV are dose related
Prolongs arly POA
Recommended
dose 800 No effect on itching In not better that spinal morphine
Clonidine
15 - 450
Improve spinal anaesthesia Hypothension
Reduce spinal LA dose Sedation
Prolongs POA Dry mouth
Recommended
dose 30 No respiratory depresion Fetal and maternal bradycardia
Midazolam* 1000-2000 Enhance POA Augments PONV?
Recommended
dose 2000?
Reduce PO analgesic doses
Reduce PONV?
Magnesium sulphate* 5, 000-100, 000
Prolongs spinal block




Reduces PO analgesic doses
Reduces postoperative
shivering
LA=Local anaesthetics. POA=Postoperative analgesia. POP=Postoperative. PONV=Postoeprative nausea and vomiting.
*Nalbuphine, midazolam and magnesium suphate are under clinical investigatior to determine its use in spinal
anaesthesia for several clinical scenarios.
Table 1. Spinal additives and some drugs under clinical research in parturients undergoing cesarean delivery with
spinal anaesthesia.
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